Neoantigens, which are mutant peptides presented on the surface of cancer cells, play an important role in eliciting immune responses. Identifying these neoantigens accurately is necessary for the development of personalized cancer vaccines. Traditionally, computational methods have primarily focused on neoantigens arising from single-nucleotide variants (SNVs) and small insertions or deletions (indels). However, a broader approach was needed due to the diverse nature of neoantigens.
In the pursuit of advancing personalized cancer immunotherapy, researchers developed NeoHunter, a new software tool designed to detect and prioritize neoantigens. Published in Quantitative Biology, the software's capabilities are detailed in the article "NeoHunter: Flexible Software for Systematically Detecting Neoantigens from Sequencing Data".
Comprehensive Detection Across Mutation Types
NeoHunter addresses many challenges of identifying neoantigens by offering a comprehensive framework that can detect neoantigens from a variety of molecular alterations, including SNVs, indels, gene fusions, and aberrant splicing. This flexibility is crucial, as it allows for the inclusion of all possible sources of neoantigens, providing a more complete view of vaccine design.
The software operates by first identifying different types of molecular alterations from next-generation sequencing (NGS) data of cancer patients. It then determines the types of human leukocyte antigen (HLA) alleles present and estimates the binding affinity between mutant peptides and HLA alleles. This estimation predicts the likelihood of a peptide being presented by an HLA molecule, forming a peptide-major histocompatibility complex (pMHC), which is essential for T-cell recognition.
Validating NeoHunter's Effectiveness
In a collaborative effort with the Tumor Neoantigen Selection Alliance (TESLA), NeoHunter was applied to cancer patients, leading to the identification and validation of several immunogenic neoantigens. The software detected 27 out of 34 neoantigens validated by TESLA, showcasing its high performance relative to existing methods. The majority of these were derived from SNVs and indels, underscoring the prevalence of these alterations in generating immunogenic neoantigens.
Further analysis revealed the influence of mutation annotation tools and NGS sequencing depth on the accuracy of neoantigen detection, emphasizing the importance of methodological precision in such analyses. The diverse mutation types detected by NeoHunter, including a small percentage from aberrant splicing and even fewer from gene fusions, highlight the complex nature of cancer genomics.
Implications for Cancer Vaccine Development
The findings from this study demonstrate the robustness of NeoHunter in identifying a wide array of neoantigens and also underline the necessity of considering various mutation types in vaccine design. As stated by the authors, "different types of mutations should be thoroughly considered when designing cancer vaccines against neoantigens." This tool is now available for free academic use, making it accessible to researchers worldwide, potentially accelerating advancements in the field of cancer immunotherapy.